Justin Matrisciano, MD
Endocrinology, Diabetes & Metabolism · Dartmouth, MANPI 1922093210
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $31,952 of the $34,521 with a category attached, or 92.6%. 21 manufacturers reported payments, led by AbbVie at 47.7% of the total. Reporting peaked in 2019 at $13,523 and has fallen 83.9% since, to $2,182 in 2022. Among endocrinology, diabetes & metabolism clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $248.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$16K
- Sanofi-aventis U.S. LLC$11K
- Boehringer Ingelheim$3K
- Lilly USA, LLC$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Abbott$162
- plus $660 from 15 others
What the payments were for
- Speaking & faculty fees$31,95293%
- Travel & lodging$6552%
- Food & beverage$1,9146%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $16,457 |
| Sanofi-aventis U.S. LLC | 25 | $10,605 |
| Boehringer Ingelheim | 8 | $2,660 |
| Lilly USA, LLC | 12 | $2,409 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 25 | $1,567 |
| Abbott | 9 | $162 |
| Novo Nordisk | 10 | $145 |
| Amgen | 7 | $122 |
| Johnson & Johnson | 4 | $80 |
| BD | 3 | $49 |
| Medtronic(2 entities) | 2 | $39 |
| Merck | 3 | $38 |
| IBSA Pharma Inc. | 2 | $31 |
| Insulet Corporation | 2 | $29 |
| Antares Pharma, Inc. | 2 | $28 |
| AstraZeneca | 1 | $21 |
| Dexcom, Inc. | 1 | $18 |
| Valeritas, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Vivus LLC | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Synthroid$16,426
- TOUJEO$5,706
- JARDIANCE$4,875
- SOLIQUA 100/33$4,771
- CYCLOSET$1,200
How this compares
$34,521 in reported general payments places this provider in the 90th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 480 | $627,553 |
| TrulicityDulaglutide | 261 | $374,585 |
| MounjaroTirzepatide | 205 | $266,945 |
| JardianceEmpagliflozin | 167 | $220,892 |
| JanuviaSitagliptin Phosphate | 140 | $163,016 |
| Tresiba Flextouch U-100Insulin Degludec | 133 | $85,574 |
| Egrifta SvTesamorelin Acetate | 12 | $83,441 |
| ForteoTeriparatide | 14 | $57,963 |
| TradjentaLinagliptin | 69 | $55,972 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 93 | $44,759 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 52 | $32,381 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 253 | $30,214 |
| RybelsusSemaglutide | 31 | $29,085 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $27,229 |
| Bydureon BciseExenatide Microspheres | 19 | $20,942 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog | $2,409 | $701,114492 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $145 | $670,695538 claims |
| Boehringer IngelheimJardiance, Tradjenta | $2,660 | $276,864236 claims |
| MerckJanuvia | $38 | $163,016140 claims |
| AstraZenecaFarxiga | $21 | $14,17817 claims |
| AbbVieSynthroid | $16,457 | $12,751136 claims |
| Sanofi-aventis U.S. LLCLantus | $10,605 | $2,72212 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $1,413156 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Dartmouth
- Jason GagliaBoston$2.4M
- Tamer YacoubFall River$775K
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Nitin TrivediWorcester$403K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Peter ButlerFlorence$216K
- Augusto Caballero-RoblesBoston$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.